User's Manual
Table Of Contents
- 1. General description
- 2. Indications
- 3. Contraindications
- 4. Warnings and precautions
- 5. Adverse events
- 6. Clinical studies
- 7. Patient selection and treatment
- 8. Patient counselling information
- 9. Declaration of conformity
- 10. Physician guidelines
- 11. Patient information
- 12. How supplied
- 13. Device description
- 14. Implant procedure
- 14.1. Necessary equipment
- 14.2. Packaging
- 14.3. Optional equipment
- 14.4. Before opening the package
- 14.5. Prior to implantation
- 14.6. Device placement
- 14.7. Choosing the type of lead
- 14.8. Shock configuration (+ -> -)
- 14.9. Measurement of thresholds at implant
- 14.10. Lead connection
- 14.11. Device implantation
- 14.12. Tests and programming
- 15. Special modes
- 16. Main functions
- 17. Patient follow-up
- 18. Physical characteristics
- 19. Electrical characteristics
- 20. Programmable parameters
- 21. Non programmable parameters
- 22. Limited warranty
- 23. Patents
- 24. Explanation of symbols
6. CLINICAL STUDIES
6. CLINICAL STUDIES
Clinical data presented in this section are from the Defender and SafeR (AAI <> DDD)
clinical studies.
PLATINIUM DR is similar in design and function to the Defender devices.
SafeR (AAI <> DDD) operation in PLATINIUM is similar to that in the Symphony pacemaker.
The data provided are applicable to PLATINIUM DR.
6.1. DEFENDER STUDY
Objectives:
The primary objectives of this study were to demonstrate a complication free rate (CFR)
comparable to that of historical controls, to demonstrate, using a chronotropic assessment
exercise protocol (CAEP), a rate response proportional to and appropriate for the level of
exercise, and to evaluate and report the incidence of adverse events.
Materials:
Each patient received one Defender IV DR 612 defibrillator, an atrial pacing and sensing
lead, and a Medtronic, Angeion, or Biotronik defibrillation lead in the U.S. or any
commercially available defibrillator lead outside the U.S.
Methods:
Investigators selected patients who survived at least one episode of cardiac arrest
(manifested by loss of consciousness) presumably due to a ventricular tachyarrhythmia or
exhibited recurrent, poorly tolerated, sustained ventricular tachycardia (VT). The protocol
required evaluation of performance and adverse events at pre-discharge, one month, three
months, six months, and (in the U.S.) every three months thereafter. At the one-month visit,
eligible patients performed a chronotropic assessment exercise protocol (CAEP) maximal
exercise test.
Study Population.
The table below summarizes inclusions.
Region Date of first
implant
Date of last
implant
Data cut-off
date
Number of
centers
Number of
patients
US 14-Dec-99 08-Mar-00 14-Mar-00 6 22
Europe 04-May-99 26-Jul-99 14-Apr-00 11 38
All 04-May-99 08-Mar-00 14-Apr-00 (Eur),
14-Mar-00 (US)
17 60
6.1.1. Complication-free rate
Only European patients followed for at least 3 months:
Symbol Parameter Defender IV DR 612
N Overall number of patients 37
16
SORIN – PLATINIUM DR – U460A